Answers are grounded in this paper and cite their sources.
Monoclonal gammopathy of undetermined significance (MGUS) and asymptomatic/smoldering myeloma (SMM) precede symptomatic myeloma (MM); however, their clinical course is characterized by significant heterogeneity [ 1 ]. Watchful wait remains the standard approach [ 2 ] but risk stratification tools may discriminate between patients at different risk for progression, and mostly include the 20-2-20 and the IMWG models, based on simple biomarkers (serum free light chain (FLCs) ratio, bone marrow clonal infiltration, serum M-protein levels) [ 3 ] and their trajectories (along with other hematological variables) in time (PANGEA models) [ 4 ]. Circulating tumor cells (CTCs-clonal plasma cells) are accurately detected in patients with symptomatic MM by next generation flow cytometry (NGF) and provide a non-invasive independent prognostic tool [ 5 , 6 , 7 ]. CTCs were first evaluated as risk factor for progression in patients with sMM and MGUS more than three decades ago [ 8 , 9 ]; however, few studies have evaluated the role of CTCs detected by sensitive NGF in modern SMM and MGUS cohorts and their potential as prognostic biomarkers [ 10 , 11 , 12 , – 13 ]. In this prospective study, we evaluated whether CTCs and their levels at diagnosis are associated with the risk of progression to symptomatic disease in patients with SMM or MGUS.
No takes yet. Share an insight, caveat, or question.
Kastritis et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: